BR112014021519A2 - - Google Patents

Info

Publication number
BR112014021519A2
BR112014021519A2 BR112014021519A BR112014021519A BR112014021519A2 BR 112014021519 A2 BR112014021519 A2 BR 112014021519A2 BR 112014021519 A BR112014021519 A BR 112014021519A BR 112014021519 A BR112014021519 A BR 112014021519A BR 112014021519 A2 BR112014021519 A2 BR 112014021519A2
Authority
BR
Brazil
Application number
BR112014021519A
Other languages
Portuguese (pt)
Other versions
BR112014021519B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112014021519A2 publication Critical patent/BR112014021519A2/pt
Publication of BR112014021519B1 publication Critical patent/BR112014021519B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112014021519-7A 2012-02-29 2013-02-27 Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto BR112014021519B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012043303 2012-02-29
JP2012-043303 2012-02-29
JP2012186534 2012-08-27
JP2012-186534 2012-08-27
PCT/JP2013/055064 WO2013129443A1 (ja) 2012-02-29 2013-02-27 新規ピペリジン化合物又はその塩

Publications (2)

Publication Number Publication Date
BR112014021519A2 true BR112014021519A2 (US07585860-20090908-C00136.png) 2017-06-20
BR112014021519B1 BR112014021519B1 (pt) 2022-05-24

Family

ID=49082638

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021519-7A BR112014021519B1 (pt) 2012-02-29 2013-02-27 Compostos de piperidina ou sais dos mesmos e inibidor seletivo de aurora a, composição farmacêutica, agente antitumoral e agente de potencialização de efeito antitumoral de um agonista de microtúbulos compreendendo os ditos compostos, bem como usos terapêuticos dos ditos composto

Country Status (21)

Country Link
US (3) US9346787B2 (US07585860-20090908-C00136.png)
EP (1) EP2821406B1 (US07585860-20090908-C00136.png)
JP (1) JP5323289B1 (US07585860-20090908-C00136.png)
KR (1) KR101677823B1 (US07585860-20090908-C00136.png)
CN (1) CN104159893B (US07585860-20090908-C00136.png)
AU (1) AU2013227024B2 (US07585860-20090908-C00136.png)
BR (1) BR112014021519B1 (US07585860-20090908-C00136.png)
CA (1) CA2865875C (US07585860-20090908-C00136.png)
DK (1) DK2821406T3 (US07585860-20090908-C00136.png)
ES (1) ES2576497T3 (US07585860-20090908-C00136.png)
HK (1) HK1199730A1 (US07585860-20090908-C00136.png)
HU (1) HUE028495T2 (US07585860-20090908-C00136.png)
IN (1) IN2014DN07283A (US07585860-20090908-C00136.png)
MX (1) MX344276B (US07585860-20090908-C00136.png)
MY (1) MY169179A (US07585860-20090908-C00136.png)
PL (1) PL2821406T3 (US07585860-20090908-C00136.png)
PT (1) PT2821406T (US07585860-20090908-C00136.png)
RU (1) RU2581834C1 (US07585860-20090908-C00136.png)
SG (1) SG11201405318PA (US07585860-20090908-C00136.png)
TW (1) TWI485146B (US07585860-20090908-C00136.png)
WO (1) WO2013129443A1 (US07585860-20090908-C00136.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
KR101430209B1 (ko) * 2014-03-06 2014-08-14 강원대학교산학협력단 단백질 키나아제 활성 측정 방법 및 이를 위한 키트
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
CN104758286B (zh) * 2015-03-05 2016-09-14 南京工业大学 1-苄基-4-(2,4-二氯苯乙胺基)哌啶在制备抗肿瘤药物中的应用
CN110088097A (zh) * 2016-12-22 2019-08-02 大鹏药品工业株式会社 取代的哌啶化合物的盐
US12036215B2 (en) 2018-05-29 2024-07-16 Taiho Pharmaceutical Co., Ltd. Antitumor agent and method for tumor therapy
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2023005957A1 (en) * 2021-07-28 2023-02-02 Jacobio Pharmaceuticals Co., Ltd. Polymorphic forms of aurora a selective inhibitors and uses thereof
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers
WO2024088193A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. Combination of aurora a and parp inhibitors for treatment of cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1828165B1 (en) * 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
EP1917259B1 (en) 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
EP1917258A2 (en) * 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US20090221599A1 (en) * 2006-03-20 2009-09-03 Edward Boyd Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
JP2009530342A (ja) 2006-03-20 2009-08-27 エフ.ホフマン−ラ ロシュ アーゲー Btkおよびsyk蛋白キナーゼを阻害する方法
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
AU2008266960A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
US8519136B2 (en) * 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
EP2411010B1 (en) * 2009-03-23 2013-11-06 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
AU2010229140A1 (en) * 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
KR101677823B1 (ko) 2016-11-18
BR112014021519B1 (pt) 2022-05-24
CA2865875A1 (en) 2013-09-06
JPWO2013129443A1 (ja) 2015-07-30
US20160228427A1 (en) 2016-08-11
DK2821406T3 (en) 2016-08-22
CN104159893A (zh) 2014-11-19
SG11201405318PA (en) 2014-11-27
US20180369224A1 (en) 2018-12-27
AU2013227024A1 (en) 2014-09-18
CN104159893B (zh) 2016-05-11
HUE028495T2 (hu) 2016-12-28
EP2821406B1 (en) 2016-06-01
MY169179A (en) 2019-02-25
KR20140129056A (ko) 2014-11-06
PT2821406T (pt) 2016-09-07
AU2013227024B2 (en) 2015-12-10
MX2014010395A (es) 2015-06-05
PL2821406T3 (pl) 2016-11-30
US9346787B2 (en) 2016-05-24
US20150045342A1 (en) 2015-02-12
US10092556B2 (en) 2018-10-09
EP2821406A1 (en) 2015-01-07
CA2865875C (en) 2016-06-21
ES2576497T3 (es) 2016-07-07
IN2014DN07283A (US07585860-20090908-C00136.png) 2015-04-24
RU2581834C1 (ru) 2016-04-20
TW201339150A (zh) 2013-10-01
EP2821406A4 (en) 2015-04-29
MX344276B (es) 2016-12-08
HK1199730A1 (zh) 2015-07-17
TWI485146B (zh) 2015-05-21
WO2013129443A1 (ja) 2013-09-06
JP5323289B1 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
BR112014017635A2 (US07585860-20090908-C00136.png)
BR112014017614A2 (US07585860-20090908-C00136.png)
BR112014017933A2 (US07585860-20090908-C00136.png)
BR112014017625A2 (US07585860-20090908-C00136.png)
BR112014017592A2 (US07585860-20090908-C00136.png)
BR112014019449A2 (US07585860-20090908-C00136.png)
BR112014017659A2 (US07585860-20090908-C00136.png)
BR112014017646A2 (US07585860-20090908-C00136.png)
BR112014017638A2 (US07585860-20090908-C00136.png)
BR112014017607A2 (US07585860-20090908-C00136.png)
BR112013027865A2 (US07585860-20090908-C00136.png)
BR112014017634A2 (US07585860-20090908-C00136.png)
BR112014017609A2 (US07585860-20090908-C00136.png)
BR112014017644A2 (US07585860-20090908-C00136.png)
BR112014017588A2 (US07585860-20090908-C00136.png)
BR112014017647A2 (US07585860-20090908-C00136.png)
BR112014017618A2 (US07585860-20090908-C00136.png)
BR112014013184A8 (US07585860-20090908-C00136.png)
BR112014017630A2 (US07585860-20090908-C00136.png)
BR112014017652A2 (US07585860-20090908-C00136.png)
BR112014017621A2 (US07585860-20090908-C00136.png)
BR112014017622A2 (US07585860-20090908-C00136.png)
BR112014017627A2 (US07585860-20090908-C00136.png)
BR112014017623A2 (US07585860-20090908-C00136.png)
BR112014017631A2 (US07585860-20090908-C00136.png)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2013, OBSERVADAS AS CONDICOES LEGAIS